Cervical Cancer Google News

HPV testing may provide better reassurance against cervical cancer than Pap ... - News-Medical.net

July 19, 2014 - 3:00am

HPV testing may provide better reassurance against cervical cancer than Pap ...
News-Medical.net
In the US, cotesting for human papilloma virus (HPV) and Pap testing for cervical cancer every 5 years for women aged 30-65 years is now recommended. However, HPV testing alone may provide better reassurance against cervical cancer than Pap testing ...

Categories: Cervical Cancer News

Dr. Zorba Paster: Don't deny daughters a life free of cervical cancer - Buffalo News

July 19, 2014 - 12:25am

Dr. Zorba Paster: Don't deny daughters a life free of cervical cancer
Buffalo News
Let me back up a bit. We now know that cervical cancer is a sexually transmitted disease, the most common STD around. If a male virgin marries a female virgin, there is no way she can get cervical cancer. Lifelong lesbians and lifelong nuns who have ...

Categories: Cervical Cancer News

HPV Test Better Than Pap for Assessing Cervical Cancer Risk: Study - Yahoo Health

July 18, 2014 - 6:33pm

Yahoo Health

HPV Test Better Than Pap for Assessing Cervical Cancer Risk: Study
Yahoo Health
NEW YORK (Reuters Health) - Testing for human papillomavirus (HPV) may be the best way to know whether a woman is at risk of developing cervical cancer in the near future, according to a new study. Negative HPV tests provided women with more reliable ...
HPV test outperforms Pap for predicting cervical cancerCBS News
HPV testing may provide better reassurance against cervical cancer than Pap ...News-Medical.net

all 16 news articles »
Categories: Cervical Cancer News

HPV Test Beats Pap Smear in Gauging Cervical Cancer Risk, Study Finds - Philly.com

July 18, 2014 - 6:12pm

HPV Test Beats Pap Smear in Gauging Cervical Cancer Risk, Study Finds
Philly.com
FRIDAY, July 18, 2014 (HealthDay News) -- A new study involving data on more than 1 million women finds the HPV test outperforming the standard Pap test in assessing cervical cancer risk. Researchers at the U.S. National Cancer Institute (NCI) conclude ...

Categories: Cervical Cancer News

HPV test outperforms Pap for predicting cervical cancer - CBS News

July 18, 2014 - 5:35pm

CBS News

HPV test outperforms Pap for predicting cervical cancer
CBS News
A new study involving data on more than 1 million women finds the HPV test outperforming the standard Pap test in assessing cervical cancer risk. Researchers at the U.S. National Cancer Institute (NCI) conclude that a negative test for HPV (human ...
HPV Test Better Than Pap for Assessing Cervical Cancer Risk: StudyYahoo Health
HPV screening test does a better job than Pap test at predicting cervical ...The Plain Dealer
HPV test best way to detect onset of cervical cancerWallStreet OTC

all 38 news articles »
Categories: Cervical Cancer News

A negative HPV test may predict lower cervical cancer risk than a negative Pap - Science Codex

July 18, 2014 - 4:35pm

A negative HPV test may predict lower cervical cancer risk than a negative Pap
Science Codex
In the US, cotesting for human papilloma virus (HPV) and Pap testing for cervical cancer every 5 years for women aged 30-65 years is now recommended. However, HPV testing alone may provide better reassurance against cervical cancer than Pap testing ...

Categories: Cervical Cancer News

HPV test better than Pap for assessing cervical cancer risk: study - Reuters

July 18, 2014 - 4:16pm

HPV test better than Pap for assessing cervical cancer risk: study
Reuters
About 12,000 U.S. women were diagnosed with cervical cancer in 2010 and about 4,000 died from the disease, according to the Centers for Disease Control and Prevention. Roughly 91 percent of cervical cancers are thought to be caused by HPV.
HPV Test Beats Pap Smear in Gauging Cervical Cancer Risk, Study FindsU.S. News & World Report
A negative HPV test may predict lower cervical cancer risk than a negative PapScience Codex

all 13 news articles »
Categories: Cervical Cancer News

A negative HPV test may predict lower cervical cancer risk than a negative Pap - EurekAlert (press release)

July 18, 2014 - 4:06pm

A negative HPV test may predict lower cervical cancer risk than a negative Pap
EurekAlert (press release)
In the US, cotesting for human papilloma virus (HPV) and Pap testing for cervical cancer every 5 years for women aged 30-65 years is now recommended. However, HPV testing alone may provide better reassurance against cervical cancer than Pap testing ...

Categories: Cervical Cancer News

Public Health Officers Trained On Cervical Cancer Screening, Management - AllAfrica.com

July 16, 2014 - 12:45pm

Public Health Officers Trained On Cervical Cancer Screening, Management
AllAfrica.com
At least 20 Public Health Personnel drawn from Western Health Regions 1 and 2 of West Coast Region and Greater Banjul Area on Thursday completed a two-day training on Cervical Cancer screening and management, at SOS village clinic in Bakoteh.

Categories: Cervical Cancer News

Cervical cancer prevention program saves lives - Medical Xpress

July 16, 2014 - 9:12am

Medical Xpress

Cervical cancer prevention program saves lives
Medical Xpress
A 23-year old federal program for the early detection and treatment of cervical cancer markedly reduces illness and death among underserved, low-income women, yet its impact has been reduced by the fact that it has reached only 10 percent of the ...

and more »
Categories: Cervical Cancer News

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ... - Pharmaceutical Business Review

July 16, 2014 - 7:31am

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ...
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has accepted Genentech's supplemental Biologics License Application (sBLA) and granted priority review for Avastin (bevacizumab) plus chemotherapy to treat women with persistent, recurrent or metastatic ...

Categories: Cervical Cancer News

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ... - Pharmaceutical Business Review

July 16, 2014 - 7:31am

FDA accepts sBLA, grants priority review for Genentech's cervical cancer ...
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has accepted Genentech's supplemental Biologics License Application (sBLA) and granted priority review for Avastin (bevacizumab) plus chemotherapy to treat women with persistent, recurrent or metastatic ...

Categories: Cervical Cancer News

Priority review for Roche's Avastin in cervical cancer - PMLiVE

July 16, 2014 - 6:58am

Priority review for Roche's Avastin in cervical cancer
PMLiVE
Roche Avastin bevacizumab cancer Roche's Avastin is to undergo an expedited review process in the US for its use in advanced cervical cancer. The FDA granted priority review status to the oncology drug for use in combination with chemotherapy for the ...

Categories: Cervical Cancer News

Roche Group's Avastin for cervical cancer given priority review status by FDA - Tech Times

July 16, 2014 - 6:32am

Tech Times

Roche Group's Avastin for cervical cancer given priority review status by FDA
Tech Times
"This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer. Treatment with Avastin plus chemotherapy may help women with these conditions ...

Categories: Cervical Cancer News

US priority review for Avastin in metastatic cervical cancer - PharmaTimes

July 16, 2014 - 5:35am

US priority review for Avastin in metastatic cervical cancer
PharmaTimes
Regulators in the USA have granted a priority review to Roche's blockbuster Avastin in another indication, this time for cervical cancer. Specifically, the US Food and Drug Administration has accepted the company's supplemental Biologics License ...

Categories: Cervical Cancer News

NBCCEDP program markedly reduces death, illness from cervical cancer - News-Medical.net

July 16, 2014 - 1:10am

NBCCEDP program markedly reduces death, illness from cervical cancer
News-Medical.net
A 23-year old federal program for the early detection and treatment of cervical cancer markedly reduces illness and death among underserved, low-income women, yet its impact has been reduced by the fact that it has reached only 10 percent of the ...

and more »
Categories: Cervical Cancer News

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer - OncLive

July 15, 2014 - 5:37pm

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer
OncLive
The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer. As part of this program, the agency plans to take action on the drug's ...

Categories: Cervical Cancer News

Roche seeks Avastin cervical-cancer indication - Medical Marketing and Media

July 15, 2014 - 4:37pm

Medical Marketing and Media

Roche seeks Avastin cervical-cancer indication
Medical Marketing and Media
Roche scored the FDA's Priority Review label for its billion-dollar drug Avastin for use among patients with persistent, recurrent or metastatic cervical cancer, when paired with chemotherapy. The Priority Review means the supplemental Biologics ...

Categories: Cervical Cancer News

Genentech aims to extend Avastin to cervical cancer - San Francisco Business Times (blog)

July 15, 2014 - 4:26pm

Genentech aims to extend Avastin to cervical cancer
San Francisco Business Times (blog)
South San Francisco-based Genentech, the U.S. biotech unit of Swiss drug maker Roche, said the Food and Drug Administration granted priority review to Avastin plus chemotherapy to treat women with persistent, recurring or metastatic cervical cancer.

Categories: Cervical Cancer News

FDA grants priority review to Avastin for advanced cervical cancer - Healio

July 15, 2014 - 4:17pm

FDA grants priority review to Avastin for advanced cervical cancer
Healio
The FDA has granted priority review to bevacizumab plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer, according to a press release issued by the drug's manufacturer. The FDA based its decision in part ...

Categories: Cervical Cancer News